Ovarian Neoplasm
37
2
5
23
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
8.1%
3 terminated out of 37 trials
88.5%
+2.0% vs benchmark
5%
2 trials in Phase 3/4
26%
6 of 23 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 23 completed trials
Clinical Trials (37)
Personalized Patient Derived Xenograft (pPDX) Modeling to Test Drug Response in Matching Host
Impact of Specific Monitoring of Intraoperative Analgesia Under General Anesthesia on Chronic Pain After Ovarian Cancer Surgery
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Feasibility Study of a 4 Stage Bowel Obstruction Cancer Diet
Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types
Survivorship Care for Women Living With Ovarian Cancer: (POSTCARE-O)
MIRRORS-RCT Pilot: Role of Robotic Interval Cytoreductive Surgery for Advanced Ovarian Cancer
Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer
Omega-3 Fatty Acid in Treating Pain in Patients With Breast or Ovarian Cancer Receiving Paclitaxel
Trabectedin/Caelyx vs Cisplatin Hypersensitivity in Relapsed Ovarian Cancer Patients Allergic to Platinum
Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer
Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer
Supportive Programs for Supporting Optimal Recovery in Participants Undergoing Gynecological Surgery
Efficacy and Safety of Involving Field Radiotherapy in the Oligo-lesions(Metastasis/Recurrent/Refractory) of Ovarian Cancer
HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life
Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer
Survival Data and Characteristics of Finisterian Patients Treated With PARP Inhibitors for Ovarian Cancer Between 2014 and 2019.